SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 351 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $22,802,567 | +41.0% | 176,136 | +5.0% | 0.02% | +37.5% |
Q4 2023 | $16,174,879 | -4.6% | 167,737 | +19.9% | 0.02% | -5.9% |
Q3 2023 | $16,958,556 | -34.1% | 139,899 | -37.8% | 0.02% | -32.0% |
Q2 2023 | $25,747,646 | -3.3% | 224,831 | +16.4% | 0.02% | -7.4% |
Q1 2023 | $26,624,897 | -25.5% | 193,172 | -29.9% | 0.03% | -28.9% |
Q4 2022 | $35,722,484 | +12.5% | 275,679 | -4.0% | 0.04% | +8.6% |
Q3 2022 | $31,751,000 | +4.0% | 287,231 | -29.5% | 0.04% | +9.4% |
Q2 2022 | $30,542,000 | -34.6% | 407,440 | -31.9% | 0.03% | -20.0% |
Q1 2022 | $46,728,000 | -43.2% | 598,162 | -34.5% | 0.04% | -9.1% |
Q4 2021 | $82,206,000 | -1.8% | 912,898 | +0.8% | 0.04% | -6.4% |
Q3 2021 | $83,725,000 | +48.5% | 905,325 | +24.8% | 0.05% | +56.7% |
Q2 2021 | $56,393,000 | +6.9% | 725,404 | +2.5% | 0.03% | +11.1% |
Q1 2021 | $52,771,000 | -36.8% | 708,050 | +44.5% | 0.03% | -34.1% |
Q4 2020 | $83,547,000 | +47.2% | 490,041 | +21.3% | 0.04% | +17.1% |
Q3 2020 | $56,746,000 | -12.0% | 404,085 | +0.4% | 0.04% | -23.9% |
Q2 2020 | $64,512,000 | +67.3% | 402,349 | +2.1% | 0.05% | +39.4% |
Q1 2020 | $38,561,000 | -28.2% | 394,192 | -5.3% | 0.03% | -15.4% |
Q4 2019 | $53,704,000 | +109.3% | 416,171 | +22.2% | 0.04% | +77.3% |
Q3 2019 | $25,657,000 | -38.4% | 340,630 | +24.3% | 0.02% | -40.5% |
Q2 2019 | $41,624,000 | +44.1% | 273,933 | +13.0% | 0.04% | +42.3% |
Q1 2019 | $28,887,000 | +16.9% | 242,352 | +7.1% | 0.03% | 0.0% |
Q4 2018 | $24,705,000 | -34.9% | 226,389 | -3.6% | 0.03% | -23.5% |
Q3 2018 | $37,944,000 | +49.3% | 234,937 | +22.2% | 0.03% | +36.0% |
Q2 2018 | $25,411,000 | -10.9% | 192,256 | -50.0% | 0.02% | -7.4% |
Q1 2018 | $28,505,000 | +132.9% | 384,731 | +74.9% | 0.03% | +145.5% |
Q4 2017 | $12,238,000 | +210.3% | 219,953 | +153.0% | 0.01% | +175.0% |
Q3 2017 | $3,944,000 | +29.7% | 86,952 | -3.7% | 0.00% | +33.3% |
Q2 2017 | $3,042,000 | -44.8% | 90,259 | -51.6% | 0.00% | -40.0% |
Q1 2017 | $5,515,000 | +174.1% | 186,295 | +153.8% | 0.01% | +150.0% |
Q4 2016 | $2,012,000 | -57.7% | 73,396 | -5.3% | 0.00% | -60.0% |
Q3 2016 | $4,760,000 | +297.3% | 77,512 | +23.4% | 0.01% | +400.0% |
Q2 2016 | $1,198,000 | -86.4% | 62,826 | -86.1% | 0.00% | -90.9% |
Q1 2016 | $8,839,000 | +204.5% | 452,810 | +501.6% | 0.01% | +266.7% |
Q4 2015 | $2,903,000 | -13.1% | 75,273 | -27.6% | 0.00% | -25.0% |
Q3 2015 | $3,339,000 | -22.1% | 103,964 | -26.2% | 0.00% | 0.0% |
Q2 2015 | $4,286,000 | +204.6% | 140,864 | +33.0% | 0.00% | +300.0% |
Q1 2015 | $1,407,000 | -72.2% | 105,948 | -69.7% | 0.00% | -80.0% |
Q4 2014 | $5,061,000 | -22.4% | 349,747 | +13.2% | 0.01% | 0.0% |
Q3 2014 | $6,519,000 | +179.5% | 308,907 | +294.5% | 0.01% | +150.0% |
Q2 2014 | $2,332,000 | +52.8% | 78,305 | +23.3% | 0.00% | +100.0% |
Q1 2014 | $1,526,000 | -45.0% | 63,526 | -53.4% | 0.00% | -66.7% |
Q4 2013 | $2,776,000 | -7.2% | 136,276 | +115.1% | 0.00% | 0.0% |
Q3 2013 | $2,992,000 | +53.4% | 63,357 | +23.5% | 0.00% | +50.0% |
Q2 2013 | $1,951,000 | -57.2% | 51,304 | -58.4% | 0.00% | -60.0% |
Q1 2013 | $4,556,000 | – | 123,324 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Asymmetry Capital Management, L.P. | 87,180 | $2,581,000 | 3.60% |
Perceptive Advisors | 1,771,029 | $52,422,000 | 2.99% |
SPHERA FUNDS MANAGEMENT LTD. | 483,047 | $14,298,000 | 2.80% |
HealthCor Management, L.P. | 1,550,000 | $45,880,000 | 2.10% |
Camber Capital Management LP | 1,350,000 | $39,960,000 | 1.62% |
Tourbillon Capital Partners, L.P. | 1,537,518 | $45,511,000 | 1.17% |
Elk Creek Partners, LLC | 562,522 | $16,651,000 | 1.02% |
EMERALD ADVISERS, LLC | 818,705 | $24,234,000 | 1.00% |
EMERALD MUTUAL FUND ADVISERS TRUST | 604,467 | $17,892,000 | 0.82% |
Carlson Capital, L.P. | 1,845,702 | $54,633,000 | 0.70% |